These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35528678)

  • 1. Tumor homing peptide modified liposomes of capecitabine for improved apoptotic activity and HER2 targeted therapy in breast cancer:
    Singh MK; Pindiprolu SKSS; Reddy Sanapalli BK; Yele V; Ganesh GNK
    RSC Adv; 2019 Aug; 9(43):24987-24994. PubMed ID: 35528678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 targeted biological macromolecule modified liposomes for improved efficacy of capecitabine in breast cancer.
    Singh MK; Pindiprolu SKSS; Sanapalli BKR; Yele V; Ganesh GNK
    Int J Biol Macromol; 2020 May; 150():631-636. PubMed ID: 32061845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies.
    Siddhartha VT; Pindiprolu SKSS; Chintamaneni PK; Tummala S; Nandha Kumar S
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):387-397. PubMed ID: 28415882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
    Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
    Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
    Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
    Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PNA-Modified Liposomes Improve the Delivery Efficacy of CAPIRI for the Synergistic Treatment of Colorectal Cancer.
    Diao W; Yang B; Sun S; Wang A; Kou R; Ge Q; Shi M; Lian B; Sun T; Wu J; Bai J; Qu M; Wang Y; Yu W; Gao Z
    Front Pharmacol; 2022; 13():893151. PubMed ID: 35784721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
    Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
    Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models.
    Chettab K; Fitzsimmons C; Novikov A; Denis M; Phelip C; Mathé D; Choffour PA; Beaumel S; Fourmaux E; Norca P; Kryza D; Evesque A; Jordheim LP; Perrial E; Matera EL; Caroff M; Kerzerho J; Dumontet C
    Front Immunol; 2023; 14():1066402. PubMed ID: 37223101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB
    Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J
    J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC.
    Pal K; Madamsetty VS; Dutta SK; Mukhopadhyay D
    Int J Nanomedicine; 2019; 14():5109-5123. PubMed ID: 31371950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lyophilized liposomal formulation of a peptidomimetic-Dox conjugate for HER2 positive breast and lung cancer.
    Sonju JJ; Shrestha P; Dahal A; Gu X; Johnson WD; Zhang D; Muthumula CMR; Meyer SA; Mattheolabakis G; Jois SD
    Int J Pharm; 2023 May; 639():122950. PubMed ID: 37059241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capmatinib suppresses LPS-induced interaction between HUVECs and THP-1 monocytes through suppression of inflammatory responses.
    Park HS; Abd El-Aty AM; Jeong JH; Lee T; Jung TW
    Biomed J; 2023 Apr; 46(2):100534. PubMed ID: 35483573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting.
    Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P
    Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.
    Wu Y; Dong Z; Wang J; Fang Q
    BMJ Open; 2022 Nov; 12(11):e065299. PubMed ID: 36379662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment.
    Chen T; Chen H; Jiang Y; Yan Q; Zheng S; Wu M
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
    Zhang SH; Zhang H; He HW; Li L; Li XQ; Zhang YP; Shao RG
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):777-88. PubMed ID: 23975242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.
    Armstrong CW; Maxwell PJ; Ong CW; Redmond KM; McCann C; Neisen J; Ward GA; Chessari G; Johnson C; Crawford NT; LaBonte MJ; Prise KM; Robson T; Salto-Tellez M; Longley DB; Waugh DJ
    Oncotarget; 2016 Feb; 7(7):7885-98. PubMed ID: 26799286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer.
    Laginha KM; Moase EH; Yu N; Huang A; Allen TM
    J Drug Target; 2008 Aug; 16(7):605-10. PubMed ID: 18686132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 + cancer.
    Sonju JJ; Dahal A; Singh SS; Gu X; Johnson WD; Muthumula CMR; Meyer SA; Jois SD
    Int J Pharm; 2022 Jan; 612():121364. PubMed ID: 34896567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.